Insight

Apr 12, 2025, 15:28

Blood Cancer UK Invests £4.9 Million to change the future of blood cancer treatment

Blood Cancer UK shared a post on LinkedIn:

“OUR BIGGEST RESEARCH INVESTMENT IN OVER A DECADE.

We’re committed to funding research that can change the future of blood cancer treatment. And we’ve just made one of our BIGGEST investments ever, £4.9 MILLION in total. Every new treatment starts with research.

So meet our 5 latest researchers working to change the future of blood cancer treatment.

Dr Charlotte Graham and her team are harnessing the power of our immune system, testing a new type of CAR-T cell therapy to find a new way of treating myeloma. £1.5million

Professor Fox and his team are trialling a new drug combination to treat Primary Central Nervous System Lymphoma (PCNSL). £750,000

Professor Wynn and his team are pushing the boundaries, developing and testing a new type of stem cell transplant for people with acute myeloid leukaemia (AML). Just under £1million.

Professor Steven Knapper and his team are testing a new treatment for acute promyelocytic leukaemia (APL) Testing a new treatment that involves taking a tablet at home instead of travelling to hospital. £750,000.

Professor David Cairns wants to find a way to use data already collected in the NHS’s electronic health records to understand how well treatments work in the long-term. Just under £1million.

This research wouldn’t be possible without your support, and we can’t wait to share updates about it with you!

Together we have one mission, to beat blood cancer.”

Blood Cancer

Manchester Cancer Research Centre shared this post, adding:

“Congratulations to Professor Rob Wynn on being awarded one of five awards from Blood Cancer UK. Rob and his team have been awarded just under £1million to develop and test a new type of stem cell transplant for people with acute myeloid leukaemia (AML).

Congratulations to the other award winners and we look forward to seeing how this research can help change the future of blood cancer.”